Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

519 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Terzolo M, Fassnacht M, Perotti P, Libé R, Kastelan D, Lacroix A, Arlt W, Haak HR, Loli P, Decoudier B, Lasolle H, Quinkler M, Haissaguerre M, Chabre O, Caron P, Stigliano A, Giordano R, Zatelli MC, Bancos I, Fragoso MCBV, Canu L, Luconi M, Puglisi S, Basile V, Reimondo G, Kroiss M, Megerle F, Hahner S, Kimpel O, Dusek T, Nölting S, Bourdeau I, Chortis V, Ettaieb MH, Cosentini D, Grisanti S, Baudin E, Berchialla P, Bovis F, Sormani MP, Bruzzi P, Beuschlein F, Bertherat J, Berruti A. Terzolo M, et al. Among authors: berruti a. Lancet Diabetes Endocrinol. 2023 Oct;11(10):720-730. doi: 10.1016/S2213-8587(23)00193-6. Epub 2023 Aug 21. Lancet Diabetes Endocrinol. 2023. PMID: 37619579 Free PMC article. Clinical Trial.
New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study.
Puglisi S, Calabrese A, Ferraù F, Violi MA, Laganà M, Grisanti S, Ceccato F, Scaroni C, Di Dalmazi G, Stigliano A, Altieri B, Canu L, Loli P, Pivonello R, Arvat E, Morelli V, Perotti P, Basile V, Berchialla P, Urru S, Fiori C, Porpiglia F, Berruti A, Pia A, Reimondo G, Cannavò S, Terzolo M. Puglisi S, et al. Among authors: berruti a. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2517-2525. doi: 10.1210/clinem/dgad199. J Clin Endocrinol Metab. 2023. PMID: 37022947
Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study.
Delbarba A, Cosentini D, Facondo P, Laganà M, Pezzaioli LC, Cremaschi V, Alberti A, Grisanti S, Cappelli C, Ferlin A, Berruti A. Delbarba A, et al. Among authors: berruti a. Front Endocrinol (Lausanne). 2023 Apr 5;14:1128061. doi: 10.3389/fendo.2023.1128061. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37077359 Free PMC article.
The Evolving Treatment Landscape of Medullary Thyroid Cancer.
Laganà M, Cremaschi V, Alberti A, Vodopivec Kuri DM, Cosentini D, Berruti A. Laganà M, et al. Among authors: berruti a. Curr Treat Options Oncol. 2023 Dec;24(12):1815-1832. doi: 10.1007/s11864-023-01145-5. Epub 2023 Nov 18. Curr Treat Options Oncol. 2023. PMID: 37979019 Free PMC article. Review.
Ascl1 and OTP tumour expressions are associated with disease-free survival in lung atypical carcinoids.
Centonze G, Maisonneuve P, Simbolo M, Lagano V, Grillo F, Prinzi N, Pusceddu S, Missiato L, Colantuono M, Sabella G, Bercich L, Mangogna A, Rolli L, Grisanti S, Benvenuti MR, Pastorino U, Roz L, Scarpa A, Berruti A, Capella C, Milione M. Centonze G, et al. Among authors: berruti a. Histopathology. 2023 May;82(6):870-884. doi: 10.1111/his.14873. Epub 2023 Feb 21. Histopathology. 2023. PMID: 36720841
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors.
Antonini S, Pedersini R, Birtolo MF, Baruch NL, Carrone F, Jaafar S, Ciafardini A, Cosentini D, Laganà M, Torrisi R, Farina D, Leonardi L, Balzarini L, Vena W, Bossi AC, Zambelli A, Lania AG, Berruti A, Mazziotti G. Antonini S, et al. Among authors: berruti a. J Endocrinol Invest. 2024 Feb;47(2):433-442. doi: 10.1007/s40618-023-02174-5. Epub 2023 Aug 17. J Endocrinol Invest. 2024. PMID: 37592052
Correction: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors.
Antonini S, Pedersini R, Birtolo MF, Baruch NL, Carrone F, Jaafar S, Ciafardini A, Cosentini D, Laganà M, Torrisi R, Farina D, Leonardi L, Balzarini L, Vena W, Bossi AC, Zambelli A, Lania AG, Berruti A, Mazziotti G. Antonini S, et al. Among authors: berruti a. J Endocrinol Invest. 2024 Mar;47(3):759. doi: 10.1007/s40618-023-02208-y. J Endocrinol Invest. 2024. PMID: 37814065 No abstract available.
Pathological Complete Response to Pembrolizumab plus Axitinib Combination following Serious Immune-Related Adverse Events in an Advanced Renal Cell Carcinoma Patient with a History of Rheumatoid Arthritis.
Bergamini M, Dalla Volta A, Valcamonico F, Caramella I, Buffoni M, Munari E, Fisogni S, Zanotelli T, Suardi NR, Berruti A. Bergamini M, et al. Among authors: berruti a. Case Rep Oncol. 2024 Jan 5;17(1):56-68. doi: 10.1159/000535460. eCollection 2024 Jan-Dec. Case Rep Oncol. 2024. PMID: 38188482 Free PMC article.
519 results